Ampio Pharmaceuticals (AMPE) Competitors $0.0029 0.00 (0.00%) As of 08/1/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock AMPE vs. EVLO, CMRA, GNCAQ, GNCA, ARDS, STAB, EFTR, CLVR, HSTO, and ONCSQShould you be buying Ampio Pharmaceuticals stock or one of its competitors? The main competitors of Ampio Pharmaceuticals include Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), eFFECTOR Therapeutics (EFTR), Clever Leaves (CLVR), Histogen (HSTO), and OncoSec Medical (ONCSQ). These companies are all part of the "pharmaceutical products" industry. Ampio Pharmaceuticals vs. Its Competitors Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma eFFECTOR Therapeutics Clever Leaves Histogen OncoSec Medical Ampio Pharmaceuticals (NYSE:AMPE) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings. Which has more volatility and risk, AMPE or EVLO? Ampio Pharmaceuticals has a beta of 4.76, suggesting that its stock price is 376% more volatile than the S&P 500. Comparatively, Evelo Biosciences has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Does the media prefer AMPE or EVLO? In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score. Company Overall Sentiment Ampio Pharmaceuticals Neutral Evelo Biosciences Neutral Which has preferable valuation & earnings, AMPE or EVLO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmpio PharmaceuticalsN/AN/A-$8.63M-$11.010.00Evelo BiosciencesN/AN/A-$114.53MN/AN/A Is AMPE or EVLO more profitable? Company Net Margins Return on Equity Return on Assets Ampio PharmaceuticalsN/A N/A N/A Evelo Biosciences N/A N/A N/A Do insiders & institutionals believe in AMPE or EVLO? 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Comparatively, 1.0% of Evelo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryAmpio Pharmaceuticals beats Evelo Biosciences on 4 of the 4 factors compared between the two stocks. Get Ampio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMPE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMPE vs. The Competition Export to ExcelMetricAmpio PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$3K$788.05M$5.48B$20.63BDividend YieldN/A4.84%4.73%3.67%P/E Ratio0.001.3728.8629.01Price / SalesN/A25.68371.4465.92Price / CashN/A19.5635.4522.82Price / Book0.006.688.264.43Net Income-$8.63M-$3.67M$3.25B$993.74M7 Day PerformanceN/A-5.23%-3.73%-3.39%1 Month PerformanceN/A-0.79%4.28%-2.10%1 Year PerformanceN/A15.44%25.85%10.09% Ampio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMPEAmpio PharmaceuticalsN/A$0.00flatN/A+1,350.0%$3KN/A0.0020EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070ARDSAridis PharmaceuticalsN/A$0.00+∞N/AN/A$5KN/A0.0030Gap UpSTABStatera BiopharmaN/A$0.00flatN/A-83.3%$5KN/A0.0020EFTReFFECTOR Therapeutics0.0972 of 5 stars$0.00+200.0%N/A-99.5%$3KN/A0.0010CLVRClever LeavesN/A$0.00flatN/AN/A$1K$17.42M0.00560HSTOHistogenN/A$0.00flatN/A-99.9%$1K$19K0.0020ONCSQOncoSec MedicalN/AN/AN/AN/A$1KN/A0.0040 Related Companies and Tools Related Companies Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Statera Biopharma Competitors eFFECTOR Therapeutics Competitors Clever Leaves Competitors Histogen Competitors OncoSec Medical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:AMPE) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredMicrosoft's Next Big Bet?Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-fre...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ampio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ampio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.